Click here to close now.

Welcome!

News Feed Item

MiMedx at SAWC Spring 2014: Multiple Studies And Clinical Experience Demonstrate Clinical And Cost Effectiveness Of EpiFix Allograft For Treatment Of Hard-to-Heal Wounds

EpiFix® is shown to promote rapid healing and return to function for patients and provide a potential for significant cost savings.

MARIETTA, Ga., April 23, 2014 /PRNewswire/ -- EpiFix®, dehydrated human amnion/chorion membrane (dHACM) allografts, were shown to be clinically and cost effective in the treatment of multiple hard-to-treat wounds like diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure ulcers (PUs), according to data and case experiences being presented at the Spring Symposium on Advanced Wound Care, the leading national wound healing conference now in its 27th year.  The symposium begins today, April 23, 2014, and concludes on April 27, 2014.

"We are pleased that two abstracts highlighting EpiFix® allografts were selected for oral presentation and one of them, authored by Charles M. Zelen, DPM, FACFAS, FACFAOM, FAPWCA; Thomas E. Serena MD, FACS and Robert J. Snyder, DPM, MSc, CWS, was selected as 3rd place for Best Oral Abstract," said Parker H. "Pete" Petit, CEO of MiMedx Group, Inc.  (NASDAQ: MDXG).

"Clinically, EpiFix® is associated with more rapid healing and prevention of longer term complications including infection and amputation," said Dr. Stephen Bergquist, Medical Director for Jackson-Madison County Hospital.  "From the cost-of-care perspective, EpiFix requires the use of fewer grafts leading to overall cost savings," he continued.

Abstracts presenting EpiFix® studies and cases are:

  • A Prospective, Randomized, Comparative Study of Weekly vs. Bi-weekly Application of Dehydrated Human Amnion/Chorion Membrane Allograft in the Management of Diabetic Foot Ulcers (Abstract #CR_055, Zelen, Serena, Snyder) demonstrated in a 12-week study period of 40 patients with a mean time to complete healing of 2.4 weeks for weekly application of EpiFix® vs. 4.1 wks for biweekly application of EpiFix®.  This shows using EpiFix® weekly heals DFUs almost twice as fast as biweekly applications of EpiFix®. Overall complete heal rate with EpiFix® in both arms was 92.5% (37/40) at 12 weeks.

 

  • A Multi-center Randomized Controlled Clinical Trial Evaluating Two Application Regimens of Dehydrated Human Amniotic Membrane and Standard of Care vs. Standard of Care Alone in the Treatment of Venous Leg Ulcers (Abstract #CS_139,Serena,  Fetterolf , Harris, Doner, Patel, Connell, DeMarco, LE, McConnell , Lullove, Taffe.) 90 patients were enrolled to date in this ongoing trial. At time of interim analysis 68 patients had completed the study: 44 ulcers were randomized to receive dHACM (1 or 2 applications) and 24 received SOC alone. Outcomes were similar within the dHACM group.  At 4 weeks, 63.6% of wounds in the dHACM  group, and 25.0% of the standard of care group demonstrated greater than 40% wound closure at 4 weeks (p=0.0023). After 4 weeks ulcers treated with dHACM had reduced by 48.9% vs 12.0% for those treated with SOC only, p=0.003.

 

  • Treatment of Stage III and Stage IV Pressure Ulcers with Dehydrated Human Amnion/Chorion Membrane (Abstract #CS_014, Bergquist) evaluated the clinical and cost effectiveness of dHACM allografts as a treatment for Stage III and IV pressure ulcers (PUs).   In Stage III cases and Stage IV cases,  PUs of varying sizes were completely healed within weeks (from 1 week for  Stage III PUs with wound size of 8.6cm2 and 2.53 cm2, to 8 weeks for a Stage IV PU with an initial wound size of 9.2 cm2 ). Cost effectiveness of dHACM for treatment of PUs was influenced by increased healing rates, velocity of healing and subsequent reduction in risk for complications.  Wound size-appropriate grafts further reduce waste and cost per treatment. 

 

  • Human Amniotic Membrane Allograft to Treat Diabetic Foot Ulcers with Exposed Bone and Tendon   (Abstract# CS_117 Pougatsch, Shum, Belczyk, Rogers) 5 consecutive diabetic neuropathic patients exhibiting wounds with exposed bone and tendon were treated with EpiFix® with the intent to gain as much coverage over the exposed deep structures in as little time as possible in preparation for split-thickness skin grafting. All 5 patients had sufficiently developed granulation tissue overlying bone and tendon structures and were ready for split-thickness skin grafting in an average of 15 days (range 9-22). 4 patients healed the split-thickness skin grafts.

 

"These data support our previously published studies relating to the significant role for EpiFix® in advanced wound care," said Bill Taylor, President and COO of MiMedx. MiMedx is the leading developer and manufacturer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane.

MiMedx is exhibiting at the conference (booth 1506), and will host In-Booth Education with speakers Steve Bergquist, MD presenting on 'Complex wounds and pressure ulcer treatment with EpiFix', and Donna Becker, MSN, ACNP-BC who will discuss 'Clinical experiences with dHACM.'  Drs. Robert Snyder, Chuck Zelen, Matthew Garoufalis and Thomas Serena will be presenting about Wound Regeneration at a Company-sponsored symposium.

About EpiFix®

EpiFix® is a human amniotic allograft tissue offering uniquely processed through the Company's proprietary PURION® Process. EpiFix® dehydrated human amnion/chorion membrane (dHACM) can reduce inflammation and reduce scar tissue formation for enhanced healing. With a variety of sizes available, EpiFix® minimizes graft waste.  The Company's PURION® Process combines cleaning, dehydration and sterilization, making EpiFix® a safe, sterilized tissue that may be stored at ambient conditions for up to 5 years.

About MiMedx

MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 225,000 allografts to date for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

SOURCE MiMedx Group, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"We have a tagline - "Power in the API Economy." What that means is everything that is built in applications and connected applications is done through APIs," explained Roberto Medrano, Executive Vice President at Akana, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
To many people, IoT is a buzzword whose value is not understood. Many people think IoT is all about wearables and home automation. In his session at @ThingsExpo, Mike Kavis, Vice President & Principal Cloud Architect at Cloud Technology Partners, discussed some incredible game-changing use cases and how they are transforming industries like agriculture, manufacturing, health care, and smart cities. He will discuss cool technologies like smart dust, robotics, smart labels, and much more. Prepare...
WebRTC converts the entire network into a ubiquitous communications cloud thereby connecting anytime, anywhere through any point. In his session at WebRTC Summit,, Mark Castleman, EIR at Bell Labs and Head of Future X Labs, will discuss how the transformational nature of communications is achieved through the democratizing force of WebRTC. WebRTC is doing for voice what HTML did for web content.
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo in Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 17th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading in...
Overgrown applications have given way to modular applications, driven by the need to break larger problems into smaller problems. Similarly large monolithic development processes have been forced to be broken into smaller agile development cycles. Looking at trends in software development, microservices architectures meet the same demands. Additional benefits of microservices architectures are compartmentalization and a limited impact of service failure versus a complete software malfunction. Th...
The 17th International Cloud Expo has announced that its Call for Papers is open. 17th International Cloud Expo, to be held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, APM, APIs, Microservices, Security, Big Data, Internet of Things, DevOps and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding bu...
The 5th International DevOps Summit, co-located with 17th International Cloud Expo – being held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the ...
SYS-CON Events announced today that Alert Logic, the leading provider of Security-as-a-Service solutions for the cloud, has been named “Bronze Sponsor” of SYS-CON's 17th International Cloud Expo® and DevOps Summit 2015 Silicon Valley, which will take place November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Alert Logic provides Security-as-a-Service for on-premises, cloud, and hybrid IT infrastructures, delivering deep security insight and continuous protection for cust...
17th Cloud Expo, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterprises ar...
While DevOps most critically and famously fosters collaboration, communication, and integration through cultural change, culture is more of an output than an input. In order to actively drive cultural evolution, organizations must make substantial organizational and process changes, and adopt new technologies, to encourage a DevOps culture. Moderated by Andi Mann, panelists discussed how to balance these three pillars of DevOps, where to focus attention (and resources), where organizations migh...
Containers have changed the mind of IT in DevOps. They enable developers to work with dev, test, stage and production environments identically. Containers provide the right abstraction for microservices and many cloud platforms have integrated them into deployment pipelines. DevOps and Containers together help companies to achieve their business goals faster and more effectively. In his session at DevOps Summit, Ruslan Synytsky, CEO and Co-founder of Jelastic, reviewed the current landscape of...
The 4th International Internet of @ThingsExpo, co-located with the 17th International Cloud Expo - to be held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA - announces that its Call for Papers is open. The Internet of Things (IoT) is the biggest idea since the creation of the Worldwide Web more than
Agile, which started in the development organization, has gradually expanded into other areas downstream - namely IT and Operations. Teams – then teams of teams – have streamlined processes, improved feedback loops and driven a much faster pace into IT departments which have had profound effects on the entire organization. In his session at DevOps Summit, Anders Wallgren, Chief Technology Officer of Electric Cloud, will discuss how DevOps and Continuous Delivery have emerged to help connect dev...
SYS-CON Events announced today that Harbinger Systems will exhibit at SYS-CON's 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Harbinger Systems is a global company providing software technology services. Since 1990, Harbinger has developed a strong customer base worldwide. Its customers include software product companies ranging from hi-tech start-ups in Silicon Valley to leading product companies in the US a...
Explosive growth in connected devices. Enormous amounts of data for collection and analysis. Critical use of data for split-second decision making and actionable information. All three are factors in making the Internet of Things a reality. Yet, any one factor would have an IT organization pondering its infrastructure strategy. How should your organization enhance its IT framework to enable an Internet of Things implementation? In his session at @ThingsExpo, James Kirkland, Red Hat's Chief Arch...